All questions are shown as received by the Trust.
Question One: How many early-stage (non-metastatic or Stages 2-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:
a. Atezolizumab (Tecentriq)
b. Durvalumab (Imfinzi)
c. Nivolumab (Opdivo)
d. Pembrolizumab (Keytruda)
e. Chemotherapy
f. Radiotherapy
g. Chemotherapy AND Radiotherapy
Question Two: How many patients has your Trust treated in total in the past 3 months for
a. Stage 2 Non Small Cell Lung Cancer
b. Stage 3 Non Small Cell Lung Cancer
Question Three: How many patients who received Pembrolizumab for Non Small Cell Lung Cancer (NSCLC) (any stage) in the last 3 months, received:
Pembrolizumab Monotherapy
a. Treatment every 3 weeks (200mg, Q3W)
b. Treatment every 6 weeks (400mg, Q6W)
Pembrolizumab in combination with chemotherapy
a. Treatment every 3 weeks (200mg, Q3W)
b. Treatment every 6 weeks (400mg, Q6W)
